Current and Possible Future Therapeutic Options for Huntington's Disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is an inherited neurodegenerative disorder caused by CAG trinucleotide repeats in the huntingtin gene (HTT).
• HD presents with motor, behavioral, and cognitive symptoms, with no current cure, necessitating symptomatic management.
• Current treatments focus on symptom relief, including medications for chorea, psychiatric issues, and mood stabilization, alongside non-drug therapies.

Purpose of the Study:

• To review the efficacy of existing Huntington's disease treatments.
• To explore the clinical trial progress of novel therapeutics targeting the disease's root cause.
• To discuss emerging therapeutic strategies aimed at reducing mutant huntingtin protein (mHTT) levels.

Main Methods:

• Review of current Huntington's disease (HD) therapeutic categories.
• Analysis of emerging therapies in clinical and pre-clinical development, including antisense oligonucleotide (ASO), RNA interference (RNAi), and gene editing technologies.
• Discussion of therapeutic targets, such as lowering mutant huntingtin protein (mHTT) and addressing neuroinflammation.

Main Results:

• Current HD therapies offer symptomatic relief but do not halt disease progression.
• Numerous novel therapeutics are in clinical trials, focusing on disease modification by reducing mHTT.
• Pre-clinical studies are exploring advanced gene-editing tools like CRISPR/Cas for potential HD treatment.

Conclusions:

• While current Huntington's disease (HD) treatments manage symptoms, they lack curative potential.
• Emerging therapies, particularly those targeting mHTT reduction via ASO, RNAi, and gene editing, show promise for disease modification.
• Continued research and clinical trials are crucial for developing effective treatments for Huntington's disease.